These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35849011)

  • 1. Diaminocyclopentane-derived
    Weber P; Mészáros Z; Jagečić D; Hribljan V; Mitrečić D; Bojarová P; Slámová K; Vrba J; Kulik N; Křen V; Stütz AE
    Chem Commun (Camb); 2022 Aug; 58(63):8838-8841. PubMed ID: 35849011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature.
    Bartolomé-Nebreda JM; Trabanco AA; Velter AI; Buijnsters P
    Expert Opin Ther Pat; 2021 Dec; 31(12):1117-1154. PubMed ID: 34176417
    [No Abstract]   [Full Text] [Related]  

  • 3. Thiamme2-G, a Novel O-GlcNAcase Inhibitor, Reduces Tau Hyperphosphorylation and Rescues Cognitive Impairment in Mice.
    Pan D; Gu JH; Zhang J; Hu Y; Liu F; Iqbal K; Cekic N; Vocadlo DJ; Dai CL; Gong CX
    J Alzheimers Dis; 2021; 81(1):273-286. PubMed ID: 33814439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based discovery and development of novel O-GlcNAcase inhibitors for the treatment of Alzheimer's disease.
    Li X; Han J; Bujaranipalli S; He J; Kim EY; Kim H; Im JH; Cho WJ
    Eur J Med Chem; 2022 Aug; 238():114444. PubMed ID: 35588599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MK-8719, a Novel and Selective
    Wang X; Li W; Marcus J; Pearson M; Song L; Smith K; Terracina G; Lee J; Hong KK; Lu SX; Hyde L; Chen SC; Kinsley D; Melchor JP; Rubins DJ; Meng X; Hostetler E; Sur C; Zhang L; Schachter JB; Hess JF; Selnick HG; Vocadlo DJ; McEachern EJ; Uslaner JM; Duffy JL; Smith SM
    J Pharmacol Exp Ther; 2020 Aug; 374(2):252-263. PubMed ID: 32493725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice.
    Hastings NB; Wang X; Song L; Butts BD; Grotz D; Hargreaves R; Fred Hess J; Hong KK; Huang CR; Hyde L; Laverty M; Lee J; Levitan D; Lu SX; Maguire M; Mahadomrongkul V; McEachern EJ; Ouyang X; Rosahl TW; Selnick H; Stanton M; Terracina G; Vocadlo DJ; Wang G; Duffy JL; Parker EM; Zhang L
    Mol Neurodegener; 2017 May; 12(1):39. PubMed ID: 28521765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly functionalized diaminocyclopentanes: A new route to potent and selective inhibitors of human O-GlcNAcase.
    Weber P; Mészáros Z; Bojarová P; Ebner M; Fischer R; Křen V; Kulik N; Müller P; Vlachová M; Slámová K; Stütz AE; Thonhofer M; Torvisco A; Wrodnigg TM; Wolfsgruber A
    Bioorg Chem; 2023 Nov; 140():106819. PubMed ID: 37666109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sugar Kick Prevents Memory Impairment.
    Rudrawar S; Ryan P
    J Med Chem; 2019 Nov; 62(22):10059-10061. PubMed ID: 31668062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo.
    Yuzwa SA; Macauley MS; Heinonen JE; Shan X; Dennis RJ; He Y; Whitworth GE; Stubbs KA; McEachern EJ; Davies GJ; Vocadlo DJ
    Nat Chem Biol; 2008 Aug; 4(8):483-90. PubMed ID: 18587388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.
    Permanne B; Sand A; Ousson S; Nény M; Hantson J; Schubert R; Wiessner C; Quattropani A; Beher D
    ACS Chem Neurosci; 2022 Apr; 13(8):1296-1314. PubMed ID: 35357812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diaminocyclopentane - l-Lysine Adducts: Potent and selective inhibitors of human O-GlcNAcase.
    Weber P; Bojarová P; Brouzdová J; Křen V; Kulik N; Stütz AE; Thonhofer M; Wrodnigg TM
    Bioorg Chem; 2024 Jul; 148():107452. PubMed ID: 38763001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 4-(Arylethynyl)piperidine Derivatives as Potent Nonsaccharide
    Cheng Z; Shang N; Wang X; Kang Y; Zhou J; Lan J; Hu J; Peng Y; Xu B
    J Med Chem; 2024 Aug; 67(16):14292-14312. PubMed ID: 39109492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.
    Liu F; Shi J; Tanimukai H; Gu J; Gu J; Grundke-Iqbal I; Iqbal K; Gong CX
    Brain; 2009 Jul; 132(Pt 7):1820-32. PubMed ID: 19451179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of O-GlcNAc alteration on Alzheimer-like neurodegeneration in SK-N-SH cells.
    Ding N; Peng P; Chu YJ; Wang JJ; Chen SY; Arulthas R; Deng YQ
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):243-248. PubMed ID: 30181664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation.
    Dorfmueller HC; Borodkin VS; Schimpl M; van Aalten DM
    Biochem J; 2009 May; 420(2):221-7. PubMed ID: 19275764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIRT1 deficiency increases O-GlcNAcylation of tau, mediating synaptic tauopathy.
    Yin X; Li Y; Fan X; Huang F; Qiu Y; Zhao C; Zhou Z; Gu Q; Xia L; Bao J; Wang X; Liu F; Qian W
    Mol Psychiatry; 2022 Oct; 27(10):4323-4334. PubMed ID: 35879403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders.
    Martínez-Viturro CM; Trabanco AA; Royes J; Fernández E; Tresadern G; Vega JA; Del Cerro A; Delgado F; García Molina A; Tovar F; Shaffer P; Ebneth A; Bretteville A; Mertens L; Somers M; Alonso JM; Bartolomé-Nebreda JM
    J Med Chem; 2020 Nov; 63(22):14017-14044. PubMed ID: 33197187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of Intracellular Tau Aggregation Regulated by OGA/OGT Inhibitors.
    Lim S; Haque MM; Nam G; Ryoo N; Rhim H; Kim YK
    Int J Mol Sci; 2015 Aug; 16(9):20212-24. PubMed ID: 26343633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation.
    Gong CX; Liu F; Grundke-Iqbal I; Iqbal K
    J Alzheimers Dis; 2006 Mar; 9(1):1-12. PubMed ID: 16627930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
    Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
    Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.